MPH966

DRUG2 trials

Sponsors

National Cancer Institute (NCI), Nelson Chao

Conditions

Bronchiolitis Obliterans SyndromeChronic Graft vs Host DiseaseChronic Graft-Versus-Host DiseaseHematologic Malignancy

Phase 1

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Active, not recruitingNCT02669251

National Cancer Institute (NCI)Bronchiolitis Obliterans Syndrome, Chronic Graft-Versus-Host Disease, Chronic Graft vs Host Disease

Start: 2016-04-28End: 2027-12-01Updated: 2026-09-16

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

WithdrawnNCT03986086

Nelson ChaoHematologic Malignancy

Start: 2021-09-30End: 2023-12-31Updated: 2020-03-20

Related Papers

Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Blood2021-11-052 citations

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Blood2020-11-052 citations